Trevi Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Trevi Therapeutics generated cash of -$31,710,000, which is less than the previous year. Cash used in financing activities reached the amount of -$7,910,000 last year. Net change in cash is therefore $19,808,000.
Cash Flow
| 2016 | -11.19M | 0 | 8.59M |
|---|---|---|---|
| 2017 | -7.97M | -13K | 21.72M |
| 2018 | -18.29M | -158K | 3.62K |
| 2019 | -23.09M | -9K | 73.21K |
| 2020 | -29M | -32K | 16.72M |
| 2021 | -28.94M | 0 | 20.77M |
| 2022 | -28.17M | -107.37M | 111.30M |
| 2023 | -31.71M | 59.42M | -7.91M |
TRVI Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 12.58M | 36.83M | 45.00M | 57.31M | 7.20M | 22.02M | 8.28M | 10.88M |
Operating activities | ||||||||
Net income | -29.06M | -29.15M | -33.94M | -32.75M | -26.05M | -20.54M | -12.86M | -11.08M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 123K | 43K | 50K | 47K | 39K | 23K | 4K | 4K |
Stock-based compensation expense | 2.24M | 2.32M | 2.54M | 2.41M | 1.12M | 0 | 205K | 142 |
| Deferred income tax benefit | 2.24M | 2.32M | 2.54M | 2.41M | 1.12M | 0 | 205K | 142 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 293K | -374K | -135K | -30 | 49K |
Inventories | 0 | 0 | 0 | -293K | 374K | 0 | 0 | 0 |
Accounts payable | -1.04M | 9K | 831K | 417K | 777K | 66K | 92K | -1.11M |
Cash generated by operating activities | -31.71M | -28.17M | -28.94M | -29M | -23.09M | -18.29M | -7.97M | -11.19M |
Investing activities | ||||||||
Purchases Of Investments | -9.93M | -126.21M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -137K | -159K | 0 | -32K | -9K | -158K | -13K | 0 |
Acquisitions Net | 0 | -829K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 59.42M | -107.37M | 0 | -32K | -9K | -158K | -13K | 0 |
Financing activities | ||||||||
Common Stock Issued | 1.71M | 105.41M | 21.18M | 3.13M | 65.1M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | -2.23M | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -9.50M | -5.83M | -68K | -13.91M | 0 | -4.81K | -8.25M | -8.59M |
Cash used in financing activities | -7.91M | 111.30M | 20.77M | 16.72M | 73.21K | 3.62K | 21.72M | 8.59M |
Net Change In Cash | 19.80M | -24.24M | -8.17M | -12.31M | 50.11M | -14.81M | 13.73M | -2.59M |
Cash at end of period | 32.39M | 12.58M | 36.83M | 45.00M | 57.31M | 7.20M | 22.02M | 8.28M |
| Data source | Data source | Data source | Data source | Data source |